Inactive Instrument

MDxHealth SA Stock Euronext Bruxelles




Biotechnology & Medical Research

Sales 2024 * 78.66M 84.43M Sales 2025 * 89.78M 96.36M Capitalization 67.17M 72.1M
Net income 2024 * -26M -27.91M Net income 2025 * -17M -18.25M EV / Sales 2024 * 2.17 x
Net Debt 2024 * 103M 111M Net Debt 2025 * 121M 130M EV / Sales 2025 * 2.09 x
P/E ratio 2024 *
-2.61 x
P/E ratio 2025 *
-3.87 x
Employees 300
Yield 2024 *
Yield 2025 *
Free-Float 93.92%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 62 19-02-17
Director of Finance/CFO 50 19-07-21
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member 73 21-09-28
Director/Board Member 52 20-07-29
Director/Board Member 59 17-10-31
More insiders
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
More about the company